SHANGHAI, August 6, 2022 /PRNewswire/ — Epigenic Therapeutics Co., Ltd., a pioneering biotechnology company dedicated to developing next-generation gene-editing therapy using epigenetic genome regulation for a wide variety of diseases, announced today today she got $20 million in financing the Angel Series and pre-A. The Series Pre-A funding is co-invested by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating.
Proceeds from the funding will be used to validate advances in the company’s proprietary epigenetic editing in non-human primates, expand expertise and capabilities, and sponsor early clinical studies.
Epigenetic modification is a natural, inherited mechanism for regulating genes in the human body without altering the underlying DNA sequence. Leveraging the company’s proprietary and patented technology platform, scientists are able to harness the endogenous epigenetic gene regulatory pathway to precisely and efficiently deliver drugs to target cells and tissues, and achieve powerful and lasting therapeutic impact. Epigenic Therapeutics has brought together highly talented scientists and industry veterans to lead discovery and development.
“Epigenetic editing is an emerging and highly differentiated gene editing technology.” Said Bob Zhangco-founder and CEO of Epigenic Therapeutics, “together with our co-founders and scientific advisors, we are able to expand our understanding of the precise regulation of the epigenetic genome and unlock its potential as a medicine for many diseases. With the funding, we will continue to expand our team and capabilities, validate the technology platform in the animal model, and accelerate our lead product from discovery to clinical development.”
“Epigenic Therapeutics has a unique position in various gene-editing therapy developers. We are excited to invest in Epigenic Therapeutics and believe this company has a strong foundation to explore and develop precise genomic medicine to benefit many patients. Reviewed by Michael Xuemanaging director of Morningside Venture Capital.
About Epigenic Therapeutics’ Technology platform
Epigenic Therapeutics’ proprietary technology platform uses its own artificial intelligence (AI) algorithms to explore and obtain an optimized CRISPR-Cas component to regulate the target gene(s) or govern the expression of one or more genes at a time without modifying the DNA sequence. Among homologous technologies, our platform is able to overcome the potential risk resulting from DNA cleavage, including but not limited to off-target effect, short half-life, and difficult d patient compliance. Combining a patented lipid nanoparticle (LNP) drug delivery system, Epigenic Therapeutics’ the platform has been proven to accurately and efficiently deliver drugs to target cells and tissues ex-vivo and live in models of ocular, neurodegeneration, metabolic and rare diseases.
About Epigenic Therapeutics
Epigenic Therapeutics is a pioneering biotechnology company dedicated to developing next-generation gene-editing therapy using epigenetic genome regulation for a variety of diseases. Founded in 2021 by leading scientists focused on the discovery of gene-editing technologies and the development of gene-editing therapies, the company has several product candidates in development, including the treatment of eye diseases, neurodegeneration, metabolic and rare. For more information, visit www.epigenictx.com
About Morningside Venture Capital
Morningside Ventures was founded in 1986 by the Chan family of hong kong. Since its inception, Morningside has focused on trends in the world’s leading life sciences and healthcare industries, expanding its scope and investment footprint across North America, Europe and Greater China. Morningside comprises a group of investment professionals who are enterprising, have deep industry knowledge and deep experience in managing venture capital. For more information, please visit http://www.morningside.com
About Kingray Capital
Kingray Capital was founded in 2018 and focuses on investment opportunities in information security, new energy, industrial intelligence, medical and healthcare, and business services. Kingray Capital is committed to helping high-tech companies grow rapidly and create long-term, stable returns for investors.
About the Trinity Innovation Fund
Trinity Innovation Fund (“TIF”) is dedicated to investing in biomedical innovations. Our Limited Partners (LPs) include renowned biopharmaceutical companies and investment institutions. Embedded in our name, TRINITY represents the core philosophy as “Triad of scientists, managers and investors, let the professionals do their own thing”. As an investor, TIF helps scientists to transform research results, managers to develop companies. Together, we turn innovation into medicine. Leveraging our deep industry knowledge and resources, we are committed to accelerating the growth of our portfolio companies through strategy optimization, key role recruitment, partnering and more.
About TigerYeah Capital
TigerYeah Capital, an independent venture capital institution under Tigermed, was founded in 2014. TigerYeah Capital focuses on equity investment in the early and growing medical and healthcare field. The management team has strong industrial experience, vast industrial resources and rich investment experience. Since its establishment, TigerYeah Capital whose investment portfolio covers medical devices, biomedicine, CRO and health food has completed nearly 100 projects with the investment of 1.5 billion yuan. By empowering invested companies, TigerYeah Capital values the development of China and the global medical and health industry and contributes to public health.
About FountainBridge Capital
Fountainbridge Capital is a forward-thinking, emerging venture capital focused on early-stage innovations. Even starting from ideas or concepts, Fountainbridge works closely with entrepreneurs and researchers to create new businesses and translate innovation into market products. Under the direction of extensive research, Fountainbridge has made exceptional investments in advanced technologies, including semiconductors, cloud computing, biotechnology and green energy, as well as consumer innovation such as new sale retail, foreign brand and consumer electronics. Being the first investor in most portfolios, Fountainbridge is the founder and also the co-founder of start-ups. With a strong ecosystem, Fountainbridge contributes to growth strategy, recruitment of top industry experts, patent application, legal advice and ongoing fundraising. Many Fountainbridge wallets have become market leaders.
SOURCE Epigenic Therapeutics